**Reviewer's report**

**Title:** Hepatic profile analyses of tipranavir in Phase II and III clinical trials

**Version:** 2 **Date:** 5 October 2009

**Reviewer:** Marina Nunez

**Reviewer's report:**

Responses are only partially satisfactory but there is improvement in the manuscript. The main problem that I see in the current form is the conclusion of the abstract. As I mentioned in my initial comments (#2) there is an attempt for the results to look "good". This has been corrected in the result sections of the abstract but not in the conclusions. I think that the authors should include a paragraph on "hepatic severe adverse events" in the conclusions because that is absolutely relevant for clinicians, instead of just concentrating on the asymptomatic transaminase elevations.